ARTES announce expansion of the management board

Langenfeld, Germany; 10th of January 2024

ARTES Biotechnology GmbH announced today that Volker Jenzelewski reinforces the executive board of ARTES as Managing Director beginning of the year. He will manage the company in close cooperation with Dr. Michael Piontek, Managing Director and founder of ARTES Biotechnology and with Dr. Melanie Piontek, Business Development Director.

Volker Jenzelewski started his career at Rhein Biotech GmbH in 1993 after graduating in biology. In positions of increasing responsibility in technical management and GMP manufacturing, Mr. Jenzelewski eventually became Director of Process Development and Head of Manufacturing at Dynavax Europe. His final responsibility was the validation of antigen production and the support of regulatory filings for HEPLISAV-B®, the lead product of Dynavax Technologies Corporation. In the years 2010 to 2013, Mr. Jenzelewski was Managing Director of EUFETS GmbH, a CDMO in the field of advanced therapy medicinal products and a BioNTech subsidiary. He advanced the operative integration of EUFETS and the expansion into mRNA manufacturing.

He joined ARTES Biotechnology GmbH in 2014 as Director of Technology, steering the company´s development and technology transfer activities and providing technical review for business decisions.

With the expansion of the management board by Volker Jenzelewski, ARTES Biotechnology strengthens its position as a first-class solution provider and expands its future activities.


ARTES Management Team, from left to right: Volker Jenzelewski (Managing Director), Melanie Piontek (Business Development Director), Michael Piontek (Managing Director)




ARTES and Basic Pharma join in a strategic Collaboration


ARTES Biotechnology and Basic Pharma join in a strategic Collaboration and Co-Marketing Partnership for Pharmaceutical Recombinant Protein Production

Geleen – Langenfeld, October 2023

ARTES Biotechnology, a leading company specializing in development and transfer of recombinant cell lines and protein production processes from microbial expression systems and Basic Pharma, a pharmaceutical company focusing on niche pharmaceutical products, are proud to announce a strategic collaboration aimed at advancing pharmaceutical innovation.

Under the terms of this collaboration agreement, ARTES Biotechnology and Basic Pharma will harness their respective expertise, cutting-edge technologies, and marketing strategies for the development and production of nonGMP recombinant proteins in a first step. This initial phase will pave the way for subsequent upgrades to meet Good Manufacturing Practice (GMP) pharmaceutical standards. The overarching objective of this alliance is to establish a streamlined supply chain process that expedites time-to-market for new pharmaceutical products.

The inaugural product to emerge from this collaboration is Human Serum Albumin (HSA), derived from the Hansenula polymorpha yeast. This initiative is partially funded by the BioMan4R2 project within the European SMP COSME program, focusing on EU resilience efforts in the health field on Biomanufacturing and MedTech areas (BMT).

ARTES Biotechnology’s Managing Director, Michael Piontek, remarked, “This alliance marks the first step in realizing our new strategy offering research reagents for non-human applications. Together with Basic Pharma, today we start with Human Serum Albumin produced from our proprietary yeast Hansenula. Tomorrow, we will expand this portfolio with further enzymes, antigens and functional proteins.”


Ralph Bosmans, Manager of Biotechnology at Basic Pharma, expressed his enthusiasm for the collaboration: “We are delighted to join forces with ARTES Biotechnology on this venture. The synergy between ARTES Biotechnology’s proficiency in recombinant cell line development and our experience in pharmaceutical development is a perfect match.” Bob Kool, Managing director at Basic Pharma further emphasized: “We are excited to embark on this strategic journey alongside ARTES Biotechnology. The fusion of our pharmaceutical development experience with their cutting-edge protein production expertise promises a dynamic partnership.”


ARTES Biotechnology GmbH 

ARTES Biotechnology GmbH is a Germany-based company specialized in development of recombinant protein production processes from microbial expression systems. The offer is particular in the development of optimized production cell lines and processes based on yeast (Hansenula, Pichia, Saccharomyces) and bacteria (E. coli). The expression platform is complemented by a unique virus-like particle (VLP) technology for antigen presentation and vaccine development. For more than 20 years, ARTES partners successfully with human and animal health companies, enzyme manufacturer, the cosmetic, diagnostic and nutrition industry. Operation worldwide takes place from its 870 sqm facilities in Langenfeld.


Basic Pharma 

Basic Pharma is a pharmaceutical company focused on the development, production, licensing, and registration of pharmaceutical niche products. The company offers a range of services, including contract manufacturing, formulation development, regulatory support, and analytical services. Founded in 2003 and headquartered in Geleen, the Netherlands, Basic Pharma’s products are sold worldwide. In 2020, Basic Pharma expanded its portfolio by inaugurating a dedicated biotechnology department focusing on the production of biologicals. This department is suitably equipped for microbial fermentation and protein purification, thereby facilitating the progression and production of recombinant proteins. Basic Pharma is a memberLifeteczone, the LifeTech networking organization of the South of the Netherlands.



The BioMan4R2 project within the European SMP COSME program offers financial support and networking for small and medium-sized companies in the biological products and medical technology manufacturing sectors that want to increase their resilience, sustainability, and competitiveness.

ARTES’ Proteins for Diagnostics

New Paper Published